Recent study shows that HIV patients are more willing to consider and use self-injectable therapy than many physicians anticipate // .
Initial results from the OpenMind study, the largest behavioural study to look at both patients' and physicians' perceptions of HIV care in treatment-experienced patients, were revealed today at EACS.
The findings are anticipated to help physicians implement improved care to HIV patients and help pave the way for better acceptance and integration of other new innovative drugs such as monoclonal antibodies that are increasingly being developed for the management of HIV and other diseases.
The study was conceived to look at attitudes to FUZEON (enfuvirtide), the first approved HIV fusion inhibitor, and an important option for treatment-experienced patients who face HIV resistance. FUZEON presents unique challenges because it is the first self-injectable antiretroviral whereas all other treatments are oral.
It was found that 76% of patients would consider using a self-injectable HIV therapy if their physician recommended it. However, only 28% of patients who are potentially eligible for FUZEON had actually discussed this injectable option with their physicians. Only 10% of eligible patients were currently prescribed FUZEON, despite the fact that it is recommended in key international HIV treatment guidelines.
This study also identifies some of the main reasons why many physicians may be reluctant to prescribe a treatment of proven efficacy and safety. The reasons include; the physicians' perception that patients would be reluctant to use a self-injectable therapy, the physicians' opinion that the patient would not be able to incorporate FUZEON into their lifestyle and the potential misconception that FUZEON is not appropriately recommended in guidelines.
Rob Horne, Professor of Psychology at the University of Brighton and OpenMind study author, said, "These new insights from thPage: 1 2 Related medicine news :1
. One in Three Heart Attack Patients Have No Chest Pains
. Amphetamines Help Recovery of Stroke Patients
. Painkillers Do Not Shorten Dying Patients Lives
. Patients With Filariasis More Prone To HIV Infection5
. Glivec - New Hope For CMC Patients6
. Patients often assume wrongly that they are allergic to penicillin7
. New FDA Approved Drug NATRECOR For Heart Failure Patients8
. Hemochromatosis Patients Blood is Safe 9
. Patients Pressure Would Result In Overprescription 10
. Risk Of Decongestants In Hypertensive Patients 11
. Interference helps Heart Patients